Balyasny Asset Management’s Elevation Oncology ELEV Stock Holding History

Balyasny Asset Management’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-12,320	Closed	-$4.52K	–	3035
2025 Q2	$4.52K	Buy	+12,320	New	+$4.11K	﹤0.01%	2731
2024 Q3	–	Sell	-2,483,645	Closed	-$6.71M	–	2836
2024 Q2	$6.71M	Sell	2,483,645 -571,834	-19%	-$2.15M	0.01%	1043
2024 Q1	$15.7M	Buy	+3,055,479	New	+$9.9M	0.03%	738

Other funds holding ELEV

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Balyasny Asset Management's ELEV Position: Q3 2025 in Review

Balyasny Asset Management sold out of Elevation Oncology (ELEV) in Q3 2025, closing a stake of 12,320 shares — an estimated $4.52K sold.

Balyasny Asset Management first reported a position in ELEV in Q1 2024 and held it in 3 quarters. The position peaked at $15.7M in Q1 2024. 1 fund tracked by Wall St. Rank holds ELEV as of Q3 2025.

Balyasny Asset Management reported no remaining Elevation Oncology position as of Q3 2025 after selling out during the quarter.
Balyasny Asset Management sold 12,320 Elevation Oncology shares in Q3 2025, an estimated $4.52K.
Balyasny Asset Management first reported a position in Elevation Oncology in Q1 2024 and held it in 3 quarters.
Balyasny Asset Management's Elevation Oncology position peaked at $15.7M in Q1 2024.
1 fund tracked by Wall St. Rank held Elevation Oncology as of Q3 2025.

Based on Balyasny Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.